Go To Main TNBC Website


  New Posts New Posts RSS Feed - ISPY 2 TRIAL
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

ISPY 2 TRIAL

 Post Reply Post Reply
Author
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12578
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Topic: ISPY 2 TRIAL
    Posted: Apr 14 2015 at 11:05pm

Novel Trial Design Streamlines Development of Breast Cancer Therapies

Developing a cancer-fighting drug can take around a billion dollars and a dozen or more years. Even then, about 40% of investigational cancer drugs fail in clinical trials. To identify effective cancer therapies more quickly and efficiently, researchers have turned to an innovative clinical trial model in which multiple treatments are investigated simultaneously and the study design is adapted as patient data accrue.

This model was used to design the Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 (ISPY 2 TRIAL), which is under way at The University of Texas MD Anderson Cancer Center and other centers. I-SPY 2, which is open to patients who have localized breast cancer, may be a harbinger of a new paradigm in cancer drug development.

To read the entire article:

http://www.mdanderson.org/publications/oncolog/previous-issues/2015-april/novel-trial-design-streamlines-development-of-breast-cancer-therapies.html

DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12578
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Jun 16 2017 at 9:55am

Data from I-SPY 2 TRIAL shows potential of a new precision medicine drug therapy for breast cancer patients

(Keytruda = Pembrolizumab)

Results from a nationwide clinical trial, conducted in part at the University of Alabama at Birmingham, has found that adding the drug pembrolizumab in combination with standard therapy before surgery shows potential for meaningful outcomes in patients with locally advanced triple negative (TNBC) or hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancers.

The findings from I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) were exclusively presented at the annual meeting of the American Society of Clinical Oncology last week.

I-SPY 2 is a clinical trial for women with newly diagnosed, locally advanced breast cancer. It is testing whether adding investigational drugs to standard chemotherapy, based on molecular tests to identify the best drug for each patient’s individual tumor type, is better than standard chemotherapy alone before having surgery.

“We found that pembrolizumab essentially more than tripled the rate of pathologic complete responses in HER2- patients in the I-SPY 2 TRIAL,” said Andres Forero, M.D., professor in the UAB Division of Hematology and Oncology, and head of the breast cancer program at UAB.

The I-SPY 2 TRIAL is a collaborative effort among academic investigators from 20 major cancer research centers across the United States and Quantum Leap Healthcare Collaborative, the U.S. Food and Drug Administration, and the Foundation for the National Institutes of Health Cancer Biomarkers Consortium, pharmaceutical and biotech companies, and patient advocates.

UAB, Alabama’s leader in personalized medicine, has actively enrolled about 150 patients in the last five years.

The I-SPY 2 TRIAL is testing the idea of tailoring treatment by using molecular tests to help identify which patients should be treated with investigational drugs. The treatment phase of the trial consists of testing multiple investigational drugs that are thought to best match the biology of each participant’s tumor. Information from each participant who completes the study treatment is also used to help decide treatment for future women who join the trial. This allows study researchers to learn more quickly which investigational drugs will be most beneficial for women with certain tumor characteristics.

In order to determine individual treatment plans, the study includes procedures such as breast MRI scans, breast core biopsies and research blood draws. It also includes chemotherapy treatment before surgery, and the possibility of an investigational drug as part of treatment.

Precision medicine techniques and drug combinations are the latest tools in harnessing the power of getting different therapies to work in more people. UAB’s breast cancer team is aggressively conducting tumor profiling early in treatment, and combining conventional treatments such as chemotherapy and radiation with new drug therapies.

The data presented at ASCO were based on results observed in patients at high risk of relapse using up-front tumor profiling. Patients were treated with weekly standard chemotherapy (paclitaxel) for 12 weeks, with or without pembrolizumab, followed by doxorubicin and cyclophosphamide every three weeks for four cycles. Sixty-nine patients were adaptively randomized to receive pembrolizumab in the trial from December 2015 until November 2016. In total, 46 patients have undergone surgery; the other 23 have on-therapy MRI assessments.

“Not all breast cancers are the same, and there has continued to be a significant gap in the treatment options available for patients with certain subtypes, particularly TNBC,” said Forero, also a senior scientist at the UAB Comprehensive Cancer Center. “The results observed in this trial not only are encouraging, but set the stage for a shift in treatment toward combinations that can make a difference in patient outcomes.”

Precision medicine techniques and drug combinations are the latest tools in harnessing the power of getting different therapies to work in more people. UAB’s breast cancer team is aggressively conducting tumor profiling early in treatment, and combining conventional treatments such as chemotherapy and radiation with new drug therapies.

“The bottom line is that the results of this trial can help make investigational drugs available to more women in the future,” Forero said. “We are hopeful that there will be new and better options available to our patients right at diagnosis.”

http://www.uab.edu/medicine/news/latest/item/1558-data-from-i-spy-2-trial-shows-potential-of-a-new-precision-medicine-drug-therapy-for-breast-cancer-patients

DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
parrynd1 View Drop Down
Newbie
Newbie
Avatar

Joined: Feb 28 2017
Location: California
Status: Offline
Points: 18
Post Options Post Options   Thanks (0) Thanks(0)   Quote parrynd1 Quote  Post ReplyReply Direct Link To This Post Posted: Jun 20 2017 at 4:19am
Not sure if this is helpful, but I recently completed a part of the I-Spy 2 trial at UCSD and had a good, not complete, but good response to the treatment I was on. My response was better on this than the results I got from AC which followed. I wasn't really sick or tired and my hair only thinned out. I'm glad to see some data being published about this trial and new ways to treat TNBC.
Dx TN IDC 9/016 Age 28, Stage 3c, Grade 3, 4.5cm, .7cm, 1/5 Nodes, BRCA -, KI-67 >90%, 6/6 I-Spy 2, 4/4 rounds DD A/C, Lumpectomy w/reduction, 3 nodes removed, weekly Taxol/Carb1/12
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 11.05
Copyright ©2001-2016 Web Wiz Ltd.